Ï㽶ÊÓƵ

J. Robinson Singleton
( out of 14 reviews )

J. Robinson Singleton, MD

Languages spoken: English

Clinical Locations

Clinical Neurosciences Center

Salt Lake City
801-585-7575

  • Dr. J. Rob Singleton is professor and vice chairman in the Ï㽶ÊÓƵ of Utah Department of Neurology and service chief for neurology at the Salt Lake City Veterans Affairs Health System. Dr. Singleton is a neuromuscular specialist with expertise in clinical investigation, electrodiagnostic evaluation, and treatment of peripheral nerve and muscle disease. His research has focused on the relationship between early hyperglycemia, dyslipidemia, and obesity and length dependent nerve injury. Since 2010, Dr. Singleton has directed the Utah CTSA award site Clinical Trial Services Foundation and oversees the 70+ protocols currently using the CTSF. He is also site principal investigator for the NINDS NeuroNEXT clinical trials consortium.

    CLINICAL AREAS OF SPECIALIZATION:

    General Neurology

    Neuromuscular Disease

    Nerve Conduction Studies and Electromyography

    Skin Biopsy for Intraepidermal Nerve Fiber Density

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Neurology)
    American Board of Psychiatry & Neurology (Sub: Clinical Neurophysiology)

    Patient Rating

    5.0 /5
    ( out of 14 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 18, 2024
    CLINICAL NEUROSCIENCES CENTER

    He was very thorough and kind.

    July 03, 2024
    CLINICAL NEUROSCIENCES CENTER

    Dr. Singleton was very friendly and professional and I felt very comfortable in his care.

    May 24, 2024
    CLINICAL NEUROSCIENCES CENTER

    Dr Singleton was very good about explaining my situation to me with care and compassion.

    May 23, 2024
    CLINICAL NEUROSCIENCES CENTER

    Provided a positive experience for a very difficult and stressful diagnosis

    December 20, 2023
    CLINICAL NEUROSCIENCES CENTER

    Very knowledgeable. Answered all questions

    October 05, 2023
    CLINICAL NEUROSCIENCES CENTER

    Dr Singleton was most impressive, thorough and professional. He was very efficient but took the time required to fully explain and inform. I

    July 06, 2023
    CLINICAL NEUROSCIENCES CENTER

    Very thankful I was referred to him. Dr Singleton was caring and I didn't feel like a stranger to him. He help me understand the results of all tests. Will return in 3 months.

    May 27, 2023
    CLINICAL NEUROSCIENCES CENTER

    I have found Dr. Singleton to be very professional and knowledgeable. He listens to the symptoms, does a complete examination, and makes recommendations based on his knowledge and experience in the field. He explains the condition in terms that are understandable.

    May 18, 2023
    CLINICAL NEUROSCIENCES CENTER

    He always makes it easy to understand. Lots of sympathy for condition.

    See More Patient Comments

  • Dr. J. Rob Singleton is professor and vice chairman in the Ï㽶ÊÓƵ of Utah Department of Neurology and service chief for neurology at the Salt Lake City Veterans Affairs Health System. Dr. Singleton is a neuromuscular specialist with expertise in clinical investigation, electrodiagnostic evaluation, and treatment of peripheral nerve and muscle disease. His research has focused on the relationship between early hyperglycemia, dyslipidemia, and obesity and length dependent nerve injury. Since 2010, Dr. Singleton has directed the Utah CTSA award site Clinical Trial Services Foundation and oversees the 70+ protocols currently using the CTSF. He is also site principal investigator for the NINDS NeuroNEXT clinical trials consortium.

    CLINICAL AREAS OF SPECIALIZATION:

    General Neurology

    Neuromuscular Disease

    Nerve Conduction Studies and Electromyography

    Skin Biopsy for Intraepidermal Nerve Fiber Density

    Board Certification and Academic Information

    Academic Departments Neurology -Primary
    Board Certification
    American Board of Psychiatry & Neurology (Neurology)
    American Board of Psychiatry & Neurology (Sub: Clinical Neurophysiology)

    Education history

    Research Fellow Neurology - Ï㽶ÊÓƵ of Michigan Research Fellow
    Ï㽶ÊÓƵ of Michigan Fellow
    Residency Neurology - Ï㽶ÊÓƵ of Michigan Hospitals Resident
    Boston City Hospital Intern
    Professional Medical Ï㽶ÊÓƵ of Colorado M.D.
    History - Davidson College B.A.

    Selected Publications

    Journal Article

    1. Stewart SL, Thomas S, Hke E, Simpson D, Singleton JR, Hke A (2021). Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy. J Peripher Nerv Syst. ()
    2. Smith AG, Singleton JR (2021). Dietary management of obesity-associated neuropathy: Implications for clinical practice and trial design. Obesity (Silver Spring), 29(12), 1990-1991. ()
    3. Singleton JR, Foster-Palmer S, Marcus RL (2021). Exercise as Treatment for Neuropathy in the Setting of Diabetes and Pre-diabetic Metabolic Syndrome: a Review of Animal Models and Human Trials. Curr Diabetes Rev. ()
    4. Bailey RR, Singleton JR, Majersik JJ (2020). Association of obesity and diabetes with physical activity and fruit and vegetable consumption in stroke survivors. Fam Pract, 38(1), 56-61. ()
    5. Freeman R, Gewandter JS, Faber CG, Gibbons C, Haroutounian S, Lauria G, Levine T, Malik RA, Singleton JR, Smith AG, Bell J, Dworkin RH, Feldman E, Herrmann DN, Hoke A, Kolb N, Mansikka H, Oaklander AL, Peltier A, Polydefkis M, Ritt E, Russell JW, Sainati S, Steiner D, Treister R, eyler N (2020). Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria. Neurology, 95(22), 1005-1014. ()
    6. Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, OSuilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C (2020). Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med, 9(11). ()
    7. Cudkowicz M, Chase MK, Coffey CS, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner JM, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA, NeuroNEXT Clinical Study Sites, Shinnar S, Patch D, Darras BT, Ellis A, Packer RJ, Marder KS, Chiriboga CA, Henchcliffe C, Moran JA, Nikolov B, Factor SA, Seeley C, Greenberg SM, Amato AA, DeGregorio S, Simuni T, Ward T, Kissel JT, Kolb SJ, Bartlett A, Quinn JF, Keith K, Levine SR, Gilles N, Coyle PK, Lamb J, Wolfe GI, Crumlish A, Mejico L, Iqbal MM, Bowen JD, Tongco C, Nabors LB, Bashir K, Benge M, McDonald CM, Henricson EK, Oskarsson B, Dobkin BH, Canamar C, Glauser TA, Woo D, Molloy A, Clark P, Vollmer TL, Stein AJ, Barohn RJ, Dimachkie MM, Le Pichon JB, Benatar MG, Steele J, Wechsler L, Clemens PR, Amity C, Holloway RG, Annis C, Goldberg MP, Andersen M, Iannaccone ST, Smith AG, Singleton JR, Doudova M, Haley EC, Quigg MS, Lowenhaupt S, Malow BA, Adkins K, Clifford DB, Teshome MA, Connolly N (2020). Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurol, 77(6), 755-763. ()
    8. Thomas S, Ajroud-Driss S, Dimachkie MM, Gibbons C, Freeman R, Simpson DM, Singleton JR, Smith AG, PNRR Study Group, Hke A (2019). Peripheral Neuropathy Research Registry: A prospective cohort. J Peripher Nerv Syst, 24(1), 39-47. ()
    9. Kolb NA, Smith AG, Singleton JR, Beck SL, Howard D, Dittus K, Karafiath S, Mooney K (2017). Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up. Support Care Cancer, 26(5), 1607-1615. ()
    10. Kluding PM, Singleton JR, Pasnoor M, Dimachkie MM, Barohn RJ, Smith AG, Marcus RL (2016). Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. Phys Ther, 97(1), 20-31. ()
    11. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K (2016). The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol, 73(7), 860-6. ()
    12. Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman BI, Tuomilehto J, Bordier L, Bauduceau B, Roche F (2016). Normative Values for Electrochemical Skin Conductances and Impact of Ethnicity on Quantitative Assessment of Sudomotor Function. Diabetes Technol Ther, 18(6), 391-8. ()
    13. Singleton JR, Smith AG, Marcus RL (2015). Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep, 15(12), 120. ()
    14. Tavakoli M, Ferdousi M, Petropoulos IN, Morris J, Pritchard N, Zhivov A, Ziegler D, Pacaud D, Romanchuk K, Perkins BA, Lovblom LE, Bril V, Singleton JR, Smith G, Boulton AJ, Efron N, Malik RA (2015). Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. Diabetes Care, 38(5), 838-43. ()
    15. Kinard KI, Smith AG, Singleton JR, Lessard MK, Katz BJ, Warner JE, Crum AV, Mifflin MD, Brennan KC, Digre KB (2015). Chronic migraine is associated with reduced corneal nerve fiber density and symptoms of dry eye. Headache, 55(4), 543-9. ()
    16. Singleton JR, Marcus RL, Lessard MK, Jackson JE, Smith AG (2014). Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol, 77(1), 146-53. ()
    17. Hamid HS, Mervak CM, Mnch AE, Robell NJ, Hayes JM, Porzio MT, Singleton JR, Smith AG, Feldman EL, Lentz SI (2014). Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. Ann Clin Transl Neurol, 1(10), 799-812. ()
    18. Singleton JR, Marcus RL, Jackson JE, K Lessard M, Graham TE, Smith AG (2014). Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol, 1(10), 844-9. ()
    19. Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR (2014). The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications, 28(4), 511-6. ()
    20. Cortez M, Singleton JR, Smith AG (2014). Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol, 126, 109-22. ()
    21. Smith AG, Kim G, Porzio M, Allen B, Koach M, Mifflin M, Digre K, Keung BM, Singleton JR (2013). Corneal confocal microscopy is efficient, well-tolerated, and reproducible. J Peripher Nerv Syst, 18(1), 54-8. ()
    22. Smith AG, Singleton JR (2008). Impaired glucose tolerance and neuropathy. Neurologist, 14(1), 23-9. ()
    23. Singleton JR (2005). Evaluation and treatment of painful peripheral polyneuropathy. Semin Neurol, 25(2), 185-95. ()
    24. Singleton JR, Smith AG, Russell JW, Feldman EL (2003). Microvascular complications of impaired glucose tolerance. Diabetes, 52(12), 2867-73. ()
    25. Singleton JR, Feldman EL (2001). Insulin-like growth factor-I in muscle metabolism and myotherapies. Neurobiol Dis, 8(4), 541-54. ()
    26. Ahnen DJ, Singleton JR, Hoops TC, Kloppel TM (1986). Posttranslational processing of secretory component in the rat jejunum by a brush border metalloprotease. J Clin Invest, 77(6), 1841-8. ()

    Editorial

    1. Callaghan BC, Singleton JR (2021). Causes and Implications of Isolated Small Fiber Neuropathy. Neurology, 97(22), 1015-1016. ()
    2. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI (2015). Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve, 53(2), 165-8. ()

    Other

    1. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan D (2021). Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection. United States. ()